Elizabeth Dudnik et al. found that BRAF mutation in NSCLC did not affect the objective response rate (25% vs. 33%, P = 1.0) and PFS (3.7 m vs. 4.1 m, P = 0.37) [16]. This evidence concerns the gene BRAF and non-small cell lung carcinoma.